Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 3/20 | 0.51 |
| ▸ | CA1 | P00915 | 3/20 | 0.51 |
| ▸ | CA2 | P00918 | 3/20 | 0.51 |
| ▸ | CA9 | Q16790 | 3/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | MAOA | P21397 | 1/20 | 0.45 |
| ▸ | MAOB | P27338 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 5/20 | 0.44 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.43 |
| ▸ | TPSD1 | Q9BZJ3 | 1/20 | 0.43 |
| ▸ | TPSG1 | Q9NRR2 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 6/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5653695 | 0.90 | TDP1 (0.61) | CA12CA1CA2CA9TDP1 | |
| SCHEMBL29256392 | 0.90 | TDP1 (0.61) | CA12CA1CA2CA9TDP1 | |
| SCHEMBL7158127 | 0.90 | TDP1 (0.61) | CA12CA1CA2CA9TDP1 | |
| SCHEMBL17286165 | 0.89 | CA12 (0.51) | CA12CA1CA2CA9TDP1 | |
| SCHEMBL25095054 | 0.89 | TDP1 (0.58) | CA12CA1CA2CA9TDP1 | |
| SCHEMBL29200251 | 0.88 | TDP1 (0.44) | CA12CA1CA2CA9TDP1 | |
| SCHEMBL29119936 | 0.88 | TDP1 (0.44) | CA12CA1CA2CA9TDP1 | |
| SCHEMBL572949 | 0.87 | TDP1 (0.56) | CA12CA1CA2CA9TDP1 | |
| SCHEMBL26894412 | 0.87 | TDP1 (0.44) | CA12CA1CA2CA9TDP1 | |
| SCHEMBL25181313 | 0.86 | GAA (0.51) | CA12CA1CA2CA9TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170183297-A1 | OMEGA-3 ANALOGUES | THE UNIVERSITY OF SYDNEY (AU) | 2017-06-29 | — | — | US | disclosed |
| WO-2015176135-A1 | OMEGA-3 ANALOGUES | THE UNIVERSITY OF SYDNEY (AU) | 2015-11-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170183297-A1 | OMEGA-3 ANALOGUES | ELOVL3, PTGER3, PTGES3 | CA12 3829/4885CA1 4681/4885CA2 4335/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.